Skip to main content
. 2002 Jun 1;16(11):1397–1411. doi: 10.1101/gad.991602

Figure 2.

Figure 2

MAM activates pNRE transcription on chromatin in vitro through an N-terminal activation domain (TAD1). (A, left panel) Analysis of the ability of various MAM proteins to activate pNRE transcription in the presence of CBF1 and ICD in vitro. The different MAM truncation or deletion mutants tested are indicated above each lane and are shown schematically at the bottom of the figure. Transcription conditions are as described for Figure 1A. (Right panel) The isolated MAM TAD1 fragment (amino acids 75–301) selectively blocks Notch transcription in vitro. Reactions either lacked the Notch enhancer complex (lane 9) or contained the complex (120nM MAM:ICD–CBF1; lanes 10–14) in the absence (lane 10) or presence of 75–301MM (480 nM, lane 11; 960 nM, lane 12), a C-terminal fragment of MAM (amino acids 301–1016 fragment, 480 nM; lane 13), or the β-catenin CTARM transactivation domain (960 nM, lane 14). (B, left panel) EMSA analysis of Notch complexes containing wild-type or mutant MAM proteins, as indicated above each lane. Reactions either lacked enhancer factors (lane 1) or contained CBF1 (lanes 2–9), the ICD (lanes 3–9), and various MAM proteins (lanes 4–9), as indicated above each lane. (Right panel) The MAM TAD1 fragment (amino acids 75–301) does not disrupt assembly of the Notch enhancer complex on DNA. The binding reactions either lacked enhancer factors (lane 10) or contained 100 nM each of CBF1 (lanes 11–15), the ICD (lanes 12–15), and 1–1016MM (lanes 14,15), either in the absence (lanes 12,14) or presence (lanes 13,15) of a fivefold excess of 75–301MM. Arrows indicate the different Notch enhancer factor:DNA complexes.